|
United Therapeutics is pleased to announce a new program to provide financial assistance in meeting out-of-pocket co-pays for eligible new or existing patients on Tyvaso and Remodulin.
|
|
Starting January 2018, eligible patients who enroll in the program may pay only $10 per co-pay for each medicine, up to $6000 per year. See below for program eligibility requirements.
|
|
For more information, talk to your health care provider or specialty pharmacy.
|
Enrollment information will be available in January 2018
at UTcopay.com, Remodulin.com, and Tyvaso.com
and from ASSIST at 1-877-864-8437.
|
|
TO ENROLL IN THIS PROGRAM, YOU MUST UNDERSTAND AND AGREE TO COMPLY WITH THE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
|
| Eligibility Requirements for this program include: |
| • |
You must be 18 years or older to use this Program |
| • |
The Program is valid only for patients with commercial (also known as private) insurance who are taking the medication for an FDA-approved indication |
| • |
Patients using Medicare, Medicaid, or any other state or federal government program to pay for their medications are not eligible. Patients who start utilizing government coverage during the term of the Program will no longer be eligible |
| • |
Eligible patients must be residents of the US or Puerto Rico |
|
| Full Terms and Conditions will be available at program launch. |
| Financial assistance options may be available for those who do not qualify for this program. Contact ASSIST for more information. |
|
|
|
|
|
This promotional communication is provided by United Therapeutics.
|
This message was sent to [email]. If you do not wish to receive e-mails
from United Therapeutics, please click here.
|
|
Please do not reply to this e-mail, as this is an unattended e-mail box.
|
Orenitram, Remodulin, and Tyvaso are registered trademarks of United Therapeutics Corporation.
|
|
© 2017 United Therapeutics Corporation. All rights reserved. US/RTO/0082
|
|
